I still like Dr. Zaius and now he is a moderator on the

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps crazyjogger925 #96782
884
I still like Dr. Zaius and now he is a moderator on the Reddit CYDY board. I have been banned from that board earlier this week. I was calling out the bashers on there and the SuperChet who is the originator of the chat board banned a few people and me for misinformation. I don’t believe I was posting misinformation but I was sure the hell correcting the bashers lies. The bashers are allowed to run rampant with lies and go unchecked with their lies on that board. SuperChet is really Jeff Beaty who is a Nominating Committee member for the 13d group and makes the final call on who to ban according to the couple of mods that apologized to me and or stated that they didn’t ban me.

This is all because SuperChet started the Chat board Reddit CYDY months ago in preparation of the 13d filing. Ol’ SuperChet is on the BOD of IncellDX and funny how he has a bashing chat board…. Hmmm… does this sound like dirty pool. Are we talking big money manipulation? Is he in it for the right reasons? I don’t think so. This makes the number one priority of the 13d group to purchase IncellDX even more cloudy for self enrichment of the share holders of IncellDX. With IncellDX being mysteriously valued at twice as much as last years offer of $80 million to Nader who turned down the proposal. Now the value is suppose to be $175 million for a lab we don’t even need. Dr. Recknor has proven our lab is sufficient.
This is very suspect to me and should be to all of the investors. Our dilution would only hurt our stock price and the value isn’t what we need or want in a overpriced lab for others self enrichment.

Then we have the basher only chat board similar to what I hear of IHUB banning pro current management people so they can continue to soft bash and convince people on the fence about which way to vote their shares. This is also the reason they have infiltrated every chat board known to CYDY investors and have been lurking and studying the boards and recruiting members to further their scam of misinformation and bashing of our investment. A group that offers nothing but bashing of our investment should be suspect for what can they do for us. Apparently all they can and want to do is to make up lies and tell them over and over until people start believing the lies. This is a mild form of brainwashing and it happens quite frequently in politics now and again. It’s not new but not often can it fooled educated investors or fool people into following a false movement. That’s what we have here with the 13d group. A movement we don’t know if it’s legit or if it’s out to screw us all out of our investment. I personally don’t trust this group and don’t respect any group that believes that a good offensive of lies and bashing with half truths is appropriate to persuade the investors.

A proper challenger for our company should be able to present a plan that would out class the current managements plan. This seems like a big chore for them. Nader has a great mission statement from last year’s shareholders meeting. Where he said as soon as we are a revenue company (this year hopefully) we will trial 10 new indications each year. With lifesaving indications being the most important. The good thing about that is that saving live is the biggest revenue indications also. So double bonus.

Then you have the 13d group not offering anything and what we know is they were not happy with us not being focused on one indications at a time and would literally just stop the other trials and focus just on HIV like they have announced over and over. Is this the business plan they hope to sway us with? Who in their right mind would put all their eggs in one basket? This sounds crazy and Nader and company have a much better plan. There is so much to be suspect about when watching the less than classy 13d group. The things we have researched and discovered about the proposed nominated directors is frightening about some of them with companies falling in value and not impressive with the rest. All of them having sold their own companies. Not what I am looking for in a BOD. I don’t want CYDY sold but want to see it progress into our own pharmaceutical Company. I don’t believe they have one candidate that out classes our current Board of Directors even with a less than honorable Dr. Patterson who has not been very impressive in his quest to take over our company at the risk of self enrichment of our company by buying IncellDX for an overinflated over twice the overall cost of what value that we need? It’s a shame that he will pull down almost $30 million on the sale. How much will he and the rest of the IncellDX/13d group profit from maybe selling our CYDY? Is that their plan? Sell us cheap before any approvals? To much to risk to buy into this group. They are just not the right group to lead us to approvals we know that are already coming soon… very soon…

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 60

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 68

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 272

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 354

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 414

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 646

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 22

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 586

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Spring Health Launches Initiative for Mental Health Relief

Updated Category News Views 472

Spring Health's Commitment to Mental Health Support In response to the recent devastation from the wildfires, Spring Health has announced a significant initiative aimed at providing mental health resources to those in distress. The company has committed $500,000 to launch a new Wildfire Mental Health Support Program aimed at individuals and families impacted by these...

Continue Reading
Serina Therapeutics Showcases Innovations at Global Conference

Updated Category News Views 263

Serina Therapeutics Takes the Stage at Major Investment Event Serina Therapeutics, Inc., also known as Serina (NYSE American: SER), is set to make an impactful presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event unfolds in New York City, where Steve Ledger, the Chief Executive Officer of Serina, will take the spotlight at...

Continue Reading
Patrick Industries Faces Scrutiny Amid Merger Plans

Updated Category News Views 48

Cracks in the Merger Deal? Nobody likes it when a seemingly routine merger suddenly faces the magnifying glass of a class action attorney. But that's where we are with Patrick Industries (NASDAQ: PATK), folks. Juan Monteverde, the big hitter from Monteverde & Associates, is eyeing this one closely. This New York-based firm, perched in the legendary Empire State Building...

Continue Reading
Revolutionary Arab Human Pangenome: Advancing Genomic Equity

Updated Category News Views 124

Groundbreaking Achievement in Genomics PacBio, a renowned leader in sequencing technology, has made a substantial contribution to global genomics with the announcement of the first Arab human pangenome. This historic achievement is powered by their innovative HiFi long-read sequencing technology, showcasing the potential of genomic science to progress health equality...

Continue Reading
RCI Hospitality Secures Significant Legal Representation Ahead of Deadline

Updated Category News Views 226

Introduction to RCI Hospitality Holdings, Inc. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) is known for its diverse portfolio in the hospitality sector. With establishments across the country, RCI focuses on providing entertainment and dining experiences through various brands. As an investor in RCI Hospitality, it’s essential to stay informed about recent legal...

Continue Reading